These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21045832)

  • 21. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
    Minami H; Kawada K; Ebi H; Kitagawa K; Kim YI; Araki K; Mukai H; Tahara M; Nakajima H; Nakajima K
    Cancer Sci; 2008 Jul; 99(7):1492-8. PubMed ID: 18477034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
    Awada A; Hendlisz A; Christensen O; Lathia CD; Bartholomeus S; Lebrun F; de Valeriola D; Brendel E; Radtke M; Delaunoit T; Piccart-Gebhart M; Gil T
    Eur J Cancer; 2012 Mar; 48(4):465-74. PubMed ID: 22285181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
    Gangadhar TC; Cohen EE; Wu K; Janisch L; Geary D; Kocherginsky M; House LK; Ramirez J; Undevia SD; Maitland ML; Fleming GF; Ratain MJ
    Clin Cancer Res; 2011 Apr; 17(7):1956-63. PubMed ID: 21447721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
    Vaishampayan UN; Burger AM; Sausville EA; Heilbrun LK; Li J; Horiba MN; Egorin MJ; Ivy P; Pacey S; Lorusso PM
    Clin Cancer Res; 2010 Jul; 16(14):3795-804. PubMed ID: 20525756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.
    Bryce AH; Rao R; Sarkaria J; Reid JM; Qi Y; Qin R; James CD; Jenkins RB; Boni J; Erlichman C; Haluska P
    Invest New Drugs; 2012 Oct; 30(5):1934-41. PubMed ID: 21881915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
    Nabhan C; Villines D; Valdez TV; Tolzien K; Lestingi TM; Bitran JD; Christner SM; Egorin MJ; Beumer JH
    Br J Cancer; 2012 Aug; 107(4):592-7. PubMed ID: 22805325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
    Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
    Brendel E; Ludwig M; Lathia C; Robert C; Ropert S; Soria JC; Armand JP
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):53-61. PubMed ID: 20821331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
    Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
    Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
    Richly H; Henning BF; Kupsch P; Passarge K; Grubert M; Hilger RA; Christensen O; Brendel E; Schwartz B; Ludwig M; Flashar C; Voigtmann R; Scheulen ME; Seeber S; Strumberg D
    Ann Oncol; 2006 May; 17(5):866-73. PubMed ID: 16500908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
    Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
    Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
    Flaig TW; Costa LJ; Gustafson DL; Breaker K; Schultz MK; Crighton F; Kim FJ; Drabkin H
    Br J Cancer; 2010 Sep; 103(6):796-801. PubMed ID: 20823888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
    Waidmann O; Hofmann WP; Zeuzem S; Trojan J
    J Hepatol; 2011 Feb; 54(2):396-8. PubMed ID: 21111506
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
    Quintela-Fandino M; Le Tourneau C; Duran I; Chen EX; Wang L; Tsao M; Bandarchi-Chamkhaleh B; Pham NA; Do T; MacLean M; Nayyar R; Tusche MW; Metser U; Wright JJ; Mak TW; Siu LL
    Mol Cancer Ther; 2010 Mar; 9(3):751-60. PubMed ID: 20197396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
    Kim C; Lee JL; Choi YH; Kang BW; Ryu MH; Chang HM; Kim TW; Kang YK
    Invest New Drugs; 2012 Feb; 30(1):306-15. PubMed ID: 20839031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
    Siu LL; Awada A; Takimoto CH; Piccart M; Schwartz B; Giannaris T; Lathia C; Petrenciuc O; Moore MJ
    Clin Cancer Res; 2006 Jan; 12(1):144-51. PubMed ID: 16397036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
    Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Lind JS; Dingemans AM; Groen HJ; Thunnissen FB; Bekers O; Heideman DA; Honeywell RJ; Giovannetti E; Peters GJ; Postmus PE; van Suylen RJ; Smit EF
    Clin Cancer Res; 2010 Jun; 16(11):3078-87. PubMed ID: 20395213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.